UNITED STATES
                SECURITIES AND EXCHANGE COMMISSION
                     Washington, D.C.  20549

                           FORM 10-QSB


[X]   QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
      ACT OF 1934

           For quarterly period ended:  March 31, 2003

[ ]   TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
      EXCHANGE ACT OF 1934


                  Commission File No.  000-30991

             SKINOVATION PHARMACEUTICAL INCORPORATED
   (Name of small business issuer as specified in its charter)


        NEVADA                                           87-0458170
(State of incorporation)                 (I.R.S. Employer Identification No.)

                      2157 S. Lincoln Street
                    Salt Lake City, Utah 84106
                          (801) 323-2395
  (Address and telephone number of principal executive offices)

Check whether the issuer (1) has filed all reports required to be filed by
Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for
such shorter period that the registrant was required to file such reports),
and (2) has been subject to such filing requirements for the past 90 days.
Yes [X]   No [  ]

As of April 17, 2003, the issuer had a total of 708,000 shares of common stock
issued and outstanding.

Transitional small business disclosure format:  Yes [ ]  No [X]

<PAGE>

                        TABLE OF CONTENTS

                  PART I: FINANCIAL INFORMATION

Item 1:  Financial Statements..............................................3

Item 2:  Plan of Operations ...............................................8

Item 3:  Controls and Procedures...........................................9

                    PART II: OTHER INFORMATION

Item 6:  Exhibits and Reports on Form 8-K .................................9

Signatures and Certifications..............................................9





                 PART I:   FINANCIAL INFORMATION


ITEM 1: FINANCIAL STATEMENTS

     The financial information set forth below with respect to our statements
of operations for the three month periods ended March 31, 2003 and 2002 is
unaudited.  This financial information, in the opinion of management, includes
all adjustments consisting of normal recurring entries necessary for the fair
presentation of such data.  The results of operations for the three months
ended March 31, 2003, are not necessarily indicative of results to be expected
for any subsequent period.





                                2

<PAGE>



             Skinovation Pharmaceutical Incorporated
                       Financial Statements
                          March 31, 2003







                                3
<PAGE>


             Skinovation Pharmaceutical Incorporated
                  (A Development Stage Company)
                          Balance Sheets


                              ASSETS

                                                     March 31,   December 31,
                                                       2003         2002
                                                  ------------- -------------
                                                    (Unaudited)

CURRENT ASSETS                                    $          -  $          -
                                                  ------------- -------------

  TOTAL ASSETS                                    $          -  $          -
                                                  ============= =============


               LIABILITIES AND STOCKHOLDER' EQUITY

CURRENT LIABILITIES

Accounts Payable - Related party                  $     33,776  $     33,776
                                                  ------------- -------------

  Total Liabilities                                     33,776        33,776
                                                  ------------- -------------
STOCKHOLDERS' EQUITY

Common Stock, $.001 par value; 50,000,000
  shares authorized; 708,000 shares
  issued and outstanding                                   708           708

Additional Paid in Capital                              25,148        25,148

Deficit Accumulated During the Development Stage       (59,632)      (59,632)
                                                  ------------- -------------

  Total Stockholders' Equity                           (33,776)      (33,776)
                                                  ------------- -------------

  TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY      $          -  $          -
                                                  ============= =============






                                4
<PAGE>




             Skinovation Pharmaceutical Incorporated
                   (A Development Stage Company)
                     Statement of Operations
                           (Unaudited)

                                                                 From
                                                                 inception on
                                     For the three For the three January 15,
                                     months ended  months ended  1988 to
                                     March 31,     March 31,     March 31,
                                     2003          2002          2003
                                     ------------- ------------- -------------

REVENUES                             $          -  $          -  $     27,937
                                     ------------- ------------- -------------
EXPENSES
  General & Administrative                      -             -       124,644
                                     ------------- ------------- -------------

    TOTAL EXPENSES                              -             -       124,644
                                     ------------- ------------- -------------
NET LOSS BEFORE DISCONTINUED
  OPERATIONS                                    -             -       (96,707)

GAIN ON DISPOSAL OF OPERATIONS                  -             -        37,075
                                     ------------- ------------- -------------

NET INCOME (LOSS)                    $          -  $          -  $    (59,632)
                                     ============= ============= =============

NET LOSS PER SHARE                   $          -  $          -  $      (0.16)
                                     ============= ============= =============

WEIGHTED AVERAGE SHARES OUTSTANDING       708,000       653,000       341,112
                                     ============= ============= =============



                                5
<PAGE>


             Skinovation Pharmaceutical Incorporated
                   (A Development Stage Company)
                     Statement of Cash Flows
                           (Unaudited)


                                                                 From
                                                                 inception on
                                                                 January 15,
                                     For the three months ended  1988 through
                                              March 31,          March 31,
                                          2003          2002     2003
                                     ------------- ------------- -------------
Cash Flows from Operating Activities

  Net Loss                           $          -  $          -  $    (59,632)
  Less  Non-cash Items:
  Shares issued for services                    -             -        10,433
  Shares issued for debt payment                -             -         1,424
  Increase in accounts payable                  -             -        33,776
  Loss on disposal of PP&E                      -             -         5,263
                                     ------------- ------------- -------------
  Net Cash Provided (Used) by
   Operating Activities                         -             -        (8,736)
                                     ------------- ------------- -------------
Cash Flows from Investing Activities
  Cash paid for PP&E                            -             -        (5,264)
                                     ------------- ------------- -------------
  Net Cash Provided (Used) by
   Investing Activities                         -             -        (5,264)
                                     ------------- ------------- -------------
Cash Flows from Financing Activities
  Cash paid for offering costs                  -             -        (7,000)
  Common stock issued for cash                  -             -        21,000
                                     ------------- ------------- -------------
  Net Cash Provided (Used) by
   Financing Activities                         -             -        14,000
                                     ------------- ------------- -------------

Increase (Decrease) in Cash                     -             -             -

Cash and Cash Equivalents at
 Beginning of Period                            -             -             -
                                     ------------- ------------- -------------
Cash and Cash Equivalents at
  End of Period                      $          -  $          -  $          -
                                     ============= ============= =============
Supplemental Cash Flow Information:

  Stock issued for debt payment      $          -  $          -  $      1,424
  Stock issued for services          $          -  $          -  $     10,433

  Cash Paid For:
    Interest                         $          -  $          -  $          -
    Income Taxes                     $          -  $          -  $          -




                                6

<PAGE>

             Skinovation Pharmaceutical Incorporated
                Notes to the Financial Statements
                          March 31, 2003


GENERAL

Skinovation Pharmaceutical Incorporated (the Company) has elected to omit
substantially all footnotes to the financial statements for the three months
ended March 31, 2003 since there have been no material changes (other than
indicated in other footnotes) to the information previously reported by the
Company in their Annual Report filed on the Form 10-KSB for the twelve months
ended December 31, 2002.

UNAUDITED INFORMATION

The information furnished herein was taken from the books and records of the
Company without audit.  However, such information reflects all adjustments
which are, in the opinion of management, necessary to properly reflect the
results of the interim period presented.  The information presented is not
necessarily indicative of the results from operations expected for the full
fiscal year.




                                7



<PAGE>


     In this report references to "Skinovation," "we," "us," and "our" refer
to Skinovation Pharmaceutical Incorporated.

                    Forward Looking Statements

      This Form 10-QSB contains certain forward-looking statements and any
statements contained in this Form 10-QSB that are not statements of historical
fact may be deemed to be forward-looking statements.  Without limiting the
foregoing, words such as "may," "will," "expect," "believe," "anticipate,"
"estimate" or "continue" or comparable terminology are intended to identify
forward-looking statements.  These statements by their nature involve
substantial risks and uncertainties, and actual results may differ materially
depending on a variety of factors, many of which are not within Skinovation's
control.  These factors include, but are not limited to, economic conditions
generally, failure by management to successfully develop business
relationships, competition within the merger and acquisitions market, lack of
operations and future changes by regulatory agencies.


ITEM 2:  PLAN OF OPERATIONS

      We are a development stage company with no assets, we have experienced
losses since our inception and we are dependent on financing to continue our
operations.  For the three month period ended March 31, 2003, we had no cash
on hand and total current liabilities of $33,776.  The current liabilities
reflect expenses related to our reporting obligations under the Exchange Act.
We have incurred expenses of $28,776 in prior years and during the year ended
December 31, 2002, we accrued another $5,000 related to the professional
services required to prepare our reports and the costs of filing the reports
with the SEC.  In the event we acquire a business opportunity we may incur
additional reporting expenses related to proxy or information statements we
may be required to provide to our stockholders which disclose the company to
be acquired's business operations, management and financial condition.

      We have no commitments for capital expenditures for the next twelve
months.  During the next twelve months we believe that our current cash needs
may be met by loans from our directors, officers and stockholders.  However,
these understandings are not formal agreements and therefore these persons are
not obligated to provide funds.  We may repay any loans, costs of services and
advancements with cash, if available, or we may convert them into common
stock.

      Our management intends to actively pursue business opportunities during
the next twelve months.  Based on current economic and regulatory conditions,
management believes that it is possible, if not probable, for a company like
ours, without many assets or liabilities, to negotiate a merger or acquisition
with a viable private company.  The opportunity arises principally because of
the high legal and accounting fees and the length of time associated with the
registration process of "going public."  However, should any of these
conditions change, it is very possible that there would be little or no
economic value for anyone taking over control of Skinovation. In addition, we
have not made a formal study of the economic potential of any business.  At
the date of this filing, we have not identified any assets or business
opportunities for acquisition.

      All risks inherent in new and inexperienced enterprises are inherent in
our business.  Potential investors must recognize that because of our limited
capital available for investigation and management's limited experience in
business analysis we may not discover or adequately evaluate adverse facts
about the business opportunity to be acquired.  Also, we intend to concentrate
our acquisition efforts on properties or businesses that we believe to be
undervalued or that we believe may realize a substantial benefit from being
publicly owned.  Investors should expect that any acquisition candidate may
have little or no operating history, or a history of losses or low
profitability.


                                8

<PAGE>


      It is emphasized that our management may effect transactions having a
potentially adverse impact upon our shareholders pursuant to the authority and
discretion of our management to complete acquisitions without submitting any
proposal to the stockholders for their consideration.

      Should a merger or acquisition prove unsuccessful, it is possible that
we may decide not to pursue further acquisition activities and management may
abandon its activities and our shares would become worthless.

ITEM 3: CONTROLS AND PROCEDURES

      During the year ended December 31, 2002, we formalized the procedures we
rely on to ensure that material information regarding our company and its
operations is provided to the public in a timely manner.  On May 8, 2003, our
principal executive and financial officer, John W. Peters, evaluated the
effectiveness of these disclosure controls and procedures and determined that
there were no significant deficiencies in these procedures.

      Also, Mr. Peters did not identify any deficiencies or material
weaknesses in our internal controls, nor did he identify fraud that involved
management or other employees who had a significant role in our internal
controls.  He did not find any deficiencies or weaknesses which would require
changes to be made or corrective actions to be taken related to our internal
controls.


PART II:  OTHER INFORMATION

ITEM 6.  EXHIBITS AND REPORTS ON FORM 8-K

Part II Exhibits

3.1      Articles of Incorporation as amended  (Incorporated by reference to
         exhibit 3.1 of the Form 10-KSB, filed March 29, 2002)

3.2      Bylaws of Skinovation (Incorporated by reference to exhibit 3.3 of
         the Form-SB, filed July 11, 2000)

99.1     Section 1350 certification

Reports on Form 8-K

      None.


                            SIGNATURES

      In accordance with the requirements of the Exchange Act, the registrant
caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.


                                  Skinovation Pharmaceutical Incorporated


                                    /s/ John W. Peters
Date: May 9, 2003              By: ____________________________________
                                   John W. Peters
                                   President, Principal Executive and
                                   Financial Officer, and Director


                                9



<PAGE>



            PRINCIPAL EXECUTIVE OFFICER CERTIFICATION

I, John W. Peters, certify that:

1.   I have reviewed this quarterly report on Form 10-QSB of Skinovation
Pharmaceutical Incorporated;

2.   Based on my knowledge, this quarterly report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to
make the statement made, in light of the circumstances under which statements
were made, not misleading with respect to the period covered by this quarterly
report;

3.   Based on my knowledge, the financial statements, and other financial
information included in this quarterly report, fairly present in all material
respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this quarterly report.

4.   The registrant's other certifying officers and I are responsible for
establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-14 and 15d-14) for the registrant and we have:

a)   designed such disclosure controls and procedures to ensure that material
information relating to the registrant, including its consolidated
subsidiaries, is made known to us by others within those entities,
particularly during the period in which this quarterly report is being
prepared;

b)   evaluated the effectiveness of the registrant's disclosure controls and
procedures as of a date within 90 days prior to the filing date of this
quarterly report (the "Evaluation Date"); and

c)   presented in this quarterly report our conclusions about the
effectiveness of the disclosure controls and procedures based on our
evaluation as of the Evaluation Date;

5.   The registrant's other certifying officers and I have disclosed, based on
our most recent evaluation, to the registrant's auditors and the audit
committee of registrant's board of directors (or persons performing the
equivalent function):

a)   all significant deficiencies in the design or operation of internal
controls which could adversely affect the registrant's ability to record,
process, summarize and report financial data and have identified for the
registrant's auditors any material weaknesses in internal controls; and

b)   any fraud, whether or not material, that involves management or other
employees who have a significant role in the registrant's internal controls;
and

6.   The registrant's other certifying officers and I have indicated in this
quarterly report whether or not there were significant changes in internal
controls or in other factors that could significantly affect internal controls
subsequent to the date of our most recent evaluation, including any corrective
actions with regard to significant deficiencies and material weaknesses.



                                 /s/ John W. Peters
Date: May 9, 2003                ___________________________________________
                                 John W. Peters, Principal Executive Officer




                                10


<PAGE>



            PRINCIPAL FINANCIAL OFFICER CERTIFICATION

I, John W. Peters, certify that:

1.   I have reviewed this quarterly report on Form 10-QSB of Skinovation
Pharmaceutical Incorporated;

2.   Based on my knowledge, this quarterly report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to
make the statement made, in light of the circumstances under which statements
were made, not misleading with respect to the period covered by this quarterly
report;

3.   Based on my knowledge, the financial statements, and other financial
information included in this quarterly report, fairly present in all material
respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this quarterly report.

4.   The registrant's other certifying officers and I are responsible for
establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-14 and 15d-14) for the registrant and we have:

a)   designed such disclosure controls and procedures to ensure that material
information relating to the registrant, including its consolidated
subsidiaries, is made known to us by others within those entities,
particularly during the period in which this quarterly report is being
prepared;

b)   evaluated the effectiveness of the registrant's disclosure controls and
procedures as of a date within 90 days prior to the filing date of this
quarterly report (the "Evaluation Date"); and

c)   presented in this quarterly report our conclusions about the
effectiveness of the disclosure controls and procedures based on our
evaluation as of the Evaluation Date;

5.   The registrant's other certifying officers and I have disclosed, based on
our most recent evaluation, to the registrant's auditors and the audit
committee of registrant's board of directors (or persons performing the
equivalent function):

a)   all significant deficiencies in the design or operation of internal
controls which could adversely affect the registrant's ability to record,
process, summarize and report financial data and have identified for the
registrant's auditors any material weaknesses in internal controls; and

b)   any fraud, whether or not material, that involves management or other
employees who have a significant role in the registrant's internal controls;
and

6.   The registrant's other certifying officers and I have indicated in this
quarterly report whether or not there were significant changes in internal
controls or in other factors that could significantly affect internal controls
subsequent to the date of our most recent evaluation, including any corrective
actions with regard to significant deficiencies and material weaknesses.


                               /s/ John W. Peters
Date: May 9, 2003              ___________________________________________
                               John W. Peters, Principal Financial Officer





                                11